Fumoleau Pierre, Campone Mario, Coudert Bruno, Mayer Françoise, Favier Laure, Ferrant Emanuelle
Centre Georges-François Leclerc, rue du Professeur Marion, 21079 Dijon.
Bull Cancer. 2007;94(7 Suppl):F147-70.
Because of the involvement of the receptors of the ErbB family in breast oncogenesis, numerous approaches aimed at targeting these receptors have been developed. A monoclonal antibody directed against the ErbB2 (HER2) receptor, trastuzumab (Herceptin), has shown a high activity in palliative, neo-adjuvant and, more recently, in adjuvant setting, and has been considered as bringing a "therapeutic revolution" in breast oncology. Other antibodies, directed against ErbB2 or EGFR, are being evaluated, especially lapatinib, which should be marketed in the next future. Combinations between targeted therapies and cytotoxic chemotherapy will certainly allow to take the greatest benefits from these new treatment approaches.
由于表皮生长因子受体（ErbB）家族的受体参与了乳腺癌的发生过程，人们已经开发出了许多针对这些受体的方法。一种针对ErbB2（HER2）受体的单克隆抗体——曲妥珠单抗（赫赛汀），在姑息治疗、新辅助治疗以及最近的辅助治疗中均显示出高活性，并且被认为给乳腺癌治疗带来了一场“治疗革命”。其他针对ErbB2或表皮生长因子受体（EGFR）的抗体正在进行评估，尤其是拉帕替尼，预计在不久的将来上市。靶向治疗与细胞毒性化疗的联合应用肯定会使这些新的治疗方法发挥出最大的效益。
